FDA Panel Supports J&J’s Antibiotic Doribax With Votes, Not Confidence
Executive Summary
An FDA panel's votes on July 16 to support Johnson & Johnson's Doribax (doripenem) reflected more the difficulty of new antibiotic drug development than the merits of J&J's particular application
You may also be interested in...
‘Structured’ Takeover: A Bitter Pill That More Will Swallow Gladly
Delayed-reward setup gives pharma the edge, but can hold advantages for acquisition targets, panel says.
Antibiotic Non-Inferiority Trials To Be Addressed By FDA Advisory Committee
Antibiotic drug sponsors may get more clarity on FDA's policy for non-inferiority margins following the conclusion of a three-day Anti-Infective Drugs Advisory Committee meeting in November
Antibiotic Non-Inferiority Trials To Be Addressed By FDA Advisory Committee
Antibiotic drug sponsors may get more clarity on FDA's policy for non-inferiority margins following the conclusion of a three-day Anti-Infective Drugs Advisory Committee meeting in November